UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

February 20, 2017

________________

 

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

 

 

Novo Allé 

DK- 2880, Bagsvaerd 

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F [X]           Form 40-F [  ]

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes [  ]            No [X]

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________

 

 

 

  

Novo Nordisk A/S - Share repurchase programme

 

 

Bagsværd, Denmark, 20 February 2017 – On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 16 billion to be executed during a 12-month period beginning 2 February 2016.

 

Under the programme initiated 2 February 2017, Novo Nordisk will repurchase B shares for an amount up to DKK 4.0 billion in the period from 2 February 2017 to 1 May 2017.

 

Since the announcement as of 13 February 2017, the following transactions have been made under the programme:

 

    Number of
B shares
    Average
purchase price
    Transaction
value, DKK
 
Accumulated, last announcement   2,032,000         476,082,248 
13 February 2017   310,000    242.06    75,039,860 
14 February 2017   270,000    240.73    64,996,779 
15 February 2017   275,000    241.17    66,322,382 
16 February 2017   280,000    244.72    68,521,686 
17 February 2017   275,000    245.82    67,599,156 
Accumulated under the programme   3,442,000         818,562,110 

 

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

 

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net purchase by Novo Nordisk of 67,710 B shares in the period from 13 February 2017 to 17

 

Page 2 of 2

 

 

February 2017. The shares in these transactions were not part of the Safe Harbour repurchase programme.

 

With the transactions stated above, Novo Nordisk owns a total of 54,560,883 B shares of DKK 0.20, corresponding to 2.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,550,000,000 including treasury shares.

 

Novo Nordisk expects to repurchase B shares for an amount up to DKK 16 billion during a 12-month period beginning 2 February 2017. As of 17 February 2017, Novo Nordisk has repurchased a total of 3,442,000 B shares equal to a transaction value of DKK 818,562,110.

 

 

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube

 

Further information

Media:
Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 786 8316 kiau@novonordisk.com
     
Investors:
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Hanna Ögren +45 3079 8519 haoe@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com

 

 

 

 

 

 

 

Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

 

Internet:

www.novonordisk.com

CVR no:

24 25 67 90

    Company announcement No 12 / 2017

 

 
 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: February 21, 2017

 

NOVO NORDISK A/S

 

Lars Fruergaard Jørgensen

Chief Executive Officer